Recent News & Research

EGFR Resisters logo
Learnings from EGFR Resisters’ Project Priority at IASLC 2019 AdvocacyCoping With Cancer

Learnings from EGFR Resisters’ Project Priority at IASLC 2019

*October 2019*  Presented by EGFR Resisters Co-Founders. * Hospitalization - While TKIs are superior to other treatments for EGFR positive lung cancer patients, there is still a large number that experience severe side effects that require urgent medical care and/or hospitalization. * Mental health - it only represents depression diagnosed…
laurabbook@gmail.com
November 8, 2019
New Data Challenge Current Standard in Treating EGFR+ Lung Cancer ResearchTreatments

New Data Challenge Current Standard in Treating EGFR+ Lung Cancer

*September 2019*  by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we're going to treat patients with EGFR-mutated cancers. At the American Society of Clinical Oncology…
laurabbook@gmail.com
November 8, 2019
targeted oncology
Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC ResearchTreatments

Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts…
laurabbook@gmail.com
November 8, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity ResearchTreatments

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI)…
laurabbook@gmail.com
September 25, 2019
cancerconnect
In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer ResearchTreatments

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect.  Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These characteristics—which include not only the particular type of…
laurabbook@gmail.com
August 12, 2019
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer Research

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several studies suggest that antibiotic use (which alters the gut microbiome) may…
laurabbook@gmail.com
August 12, 2019